Compare Stocks

→ Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMMB Chemomab Therapeutics	$0.64 -3.0%	$0.73	$0.42 ▼ $1.89	$7.07M	0.36	188,620 shs	23,560 shs
IMV IMV		$0.66	$0.48 ▼ $12.70	$9.63M	0.95	233,607 shs	44,800 shs
MRKR Marker Therapeutics	$4.36	$4.28	$0.76 ▼ $9.68	$38.80M	1.5	20,321 shs	12,556 shs
ORGS Orgenesis	$0.51	$0.65	$0.25 ▼ $1.50	$17.42M	1.07	213,963 shs	24,467 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMMB Chemomab Therapeutics	-1.64%	-5.86%	-12.02%	+31.80%	-56.93%
IMV IMV	0.00%	0.00%	0.00%	0.00%	+6.80%
MRKR Marker Therapeutics	-0.80%	+6.46%	+0.81%	-0.57%	+436.83%
ORGS Orgenesis	+2.17%	+2.58%	-39.74%	+65.19%	-54.00%

The Next Step of Their Control Is Here … (Ad)

Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.

4 simple steps to protect your privacy and money before it’s too late.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMMB Chemomab Therapeutics	2.9147 of 5 stars	3.3	5.0	0.0	0.0	2.5	1.7	0.6
IMV IMV	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ORGS Orgenesis	0.7304 of 5 stars	0.0	3.0	0.0	4.4	1.6	1.7	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMMB Chemomab Therapeutics	2.67	Moderate Buy	$7.00	993.92% Upside
IMV IMV	2.00	Hold	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A
ORGS Orgenesis	N/A	N/A	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$1.54 per share	N/A
IMV IMV	$330K	0.00	N/A	N/A	($0.69) per share	0.00
MRKR Marker Therapeutics	$3.31M	11.72	N/A	N/A	$1.58 per share	2.76
ORGS Orgenesis	$530K	32.87	N/A	N/A	($0.66) per share	-0.77

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMMB Chemomab Therapeutics	-$24.22M	-$2.12	N/A	N/A	N/A	N/A	-114.00%	-88.53%	5/9/2024 (Confirmed)
IMV IMV	-$37.99M	-$4.59	N/A	N/A	N/A	-11,547.42%	-12,695.41%	-104.84%	N/A
MRKR Marker Therapeutics	-$8.24M	N/A	0.00	∞	N/A	-142.62%	-39.89%	-25.45%	5/21/2024 (Estimated)
ORGS Orgenesis	-$55.36M	-$0.91	N/A	∞	N/A	-91.25%	-590.97%	-126.17%	5/8/2024 (Estimated)

Latest MRKR, ORGS, IMV, and CMMB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/9/2024	N/A	CMMB Chemomab Therapeutics	-$0.20	N/A	+$0.20	N/A	N/A	N/A
3/7/2024	12/31/2023	CMMB Chemomab Therapeutics	-$0.40	-$0.26	+$0.14	-$0.26	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A
IMV IMV	N/A	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A
ORGS Orgenesis	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMMB Chemomab Therapeutics	N/A	4.32	4.32
IMV IMV	N/A	2.93	2.93
MRKR Marker Therapeutics	N/A	5.57	5.57
ORGS Orgenesis	1.48	0.25	0.25

Ownership

Institutional Ownership

Company	Institutional Ownership
CMMB Chemomab Therapeutics	46.05%
IMV IMV	15.37%
MRKR Marker Therapeutics	22.39%
ORGS Orgenesis	22.56%

Insider Ownership

Company	Insider Ownership
CMMB Chemomab Therapeutics	11.91%
IMV IMV	0.33%
MRKR Marker Therapeutics	24.10%
ORGS Orgenesis	7.14%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CMMB Chemomab Therapeutics	20	11.05 million	9.73 million	Not Optionable
IMV IMV	97	11.71 million	11.67 million	Optionable
MRKR Marker Therapeutics	8	8.90 million	6.76 million	Not Optionable
ORGS Orgenesis	167	34.35 million	31.90 million	Optionable

MRKR, ORGS, IMV, and CMMB Headlines

Source	Headline
	Orgenesis (NASDAQ:ORGS) Shares Down 3.3% americanbankingnews.com - April 25 at 1:48 AM
	Orgenesis secures $2.3 million investment and strategic partnership investing.com - April 17 at 11:58 AM
	Orgenesis Inc.: Orgenesis Provides Year End Business Update finanznachrichten.de - April 17 at 9:28 AM
	Orgenesis Provides Year End Business Update globenewswire.com - April 15 at 5:07 PM
	Germfree partners with Orgenesis to enhance CGT production investing.com - April 11 at 7:22 PM
	Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility globenewswire.com - April 10 at 12:00 PM
	Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference globenewswire.com - March 18 at 8:30 AM
	Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes globenewswire.com - March 13 at 8:30 AM
	Orgenesis files patent for modified chimeric antigen receptor (car) molecule with enhanced anti-tumor activity pharmaceutical-technology.com - March 12 at 12:52 PM
	Registered Student Organizations utsa.edu - March 4 at 1:34 PM
	Orgenesis Inc. Announces $2.3 Million Private Placement globenewswire.com - March 4 at 8:30 AM
	Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing globenewswire.com - February 29 at 8:30 AM
	Orgenesis Inc. (ORGS) finance.yahoo.com - February 23 at 2:21 PM
	Orgenesis Inc ORGS morningstar.com - February 22 at 9:04 PM
	EXCLUSIVE: Orgenesis Acquires Control of Octomera, Takes One Step Closer To Progressing Its Decentralized Immuno-Oncology Portfolio To Clinic msn.com - January 31 at 10:11 AM
	Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic finance.yahoo.com - January 31 at 10:11 AM
	Cadet Organizations ung.edu - January 19 at 11:37 PM
	Too many news orgs adopt right-wing frames about trans people niemanlab.org - January 11 at 12:04 PM
	Orgenesis Inc. (ORGS) Stock Historical Prices & Data - Yahoo Finance finance.yahoo.com - January 8 at 2:42 PM
	Religious Organizations uml.edu - January 6 at 11:27 PM
	Cisco’s AI Asst for Security to reframe orgs’ view of cybersecurity outcomes businessmirror.com.ph - December 28 at 11:31 PM
	Analysts Expect Orgenesis Inc. (NASDAQ:ORGS) To Breakeven Soon finance.yahoo.com - November 22 at 7:49 AM
	Orgenesis Inc.: Orgenesis Provides Business Update for the Third Quarter of 2023 finanznachrichten.de - November 15 at 8:44 PM
	Right-Wing Orgs are Using a Social Media Loophole to Skirt Hate-Speech Rules rollingstone.com - November 14 at 5:28 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Chemomab Therapeutics

NASDAQ:CMMB

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

IMV

NASDAQ:IMV

IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.

Marker Therapeutics

NASDAQ:MRKR

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company also develops MT-401-OTS, which is in phase 1 clinical trial for the treatment of acute myeloid leukemia; and MT-601 which is in phase 1 clinical trial for the treatment of lymphoma, as well as in phase 1/2 clinical trial for the treatment of pancreatic cancer. Marker Therapeutics is headquartered in Houston, Texas.

Orgenesis

NASDAQ:ORGS

Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial